Krasnow Stephanie M, Rubin Clinton T, Roeland Eric J, Horak Fay B, Stoyles Sydnee A, Dieckmann Nathan F, Braun Kendra N, Winters-Stone Kerri M
Division of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland, OR.
Stony Brook University, Stony Brook, NY.
JCO Oncol Pract. 2025 May 15:OP2400961. doi: 10.1200/OP-24-00961.
Chemotherapy-induced peripheral neuropathy (CIPN) can have deleterious effects on mobility and quality of life in people with cancer. Vibration therapy shows promise as a CIPN intervention but is understudied. We investigated the feasibility and preliminary efficacy of low-intensity vibration (LIV) in cancer survivors with CIPN.
We conducted a pilot randomized controlled trial in adult cancer survivors with persistent CIPN symptoms. Participants were randomly assigned to twice-daily LIV sessions (10 min/session; 30 Hz, 0.4 g) for 12 weeks or usual care (UC). We assessed feasibility by accrual, retention, adherence, and adverse event (AE) reporting. We evaluated preliminary efficacy by changes in patient-reported CIPN symptoms (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity), pain (Brief Pain Inventory), fatigue (Patient-Reported Outcome Measurement Information System Fatigue), and physical functioning (Late-Life Function and Disability Instrument) and objectively measured physical functioning (chair stand time, gait speed), stability (postural sway), and mobility (Timed-Up-and-Go). Linear regression models were used to generate effect size estimates (Cohen's d).
We accrued 95% of our target sample (n = 38, mean age: 62.6 ± 9.9 years, 89% female, median time since chemotherapy completion: 18 [6-39] months), with 20 participants randomly assigned to LIV and 18 to UC. Trial retention was 97% and mean adherence to LIV was 77% ± 18%. There were no serious AEs. Compared with UC, LIV participants reported greater improvements in sensory neuropathy symptoms (LIV, +1.4 ± 3.3 points; UC, +0.2 ± 2.8 points; Cohen's d = 0.45) and basic lower extremity function (LIV, +5.3 ± 8.5 points; UC, -0.7 ± 9.2 points; Cohen's d = 0.80), with moderate-to-large effect sizes for changes in stability, mobility, and gait (Cohen's d = 0.60-0.66).
LIV is safe, feasible, and shows preliminary efficacy for CIPN symptom relief and improving physical functioning in cancer survivors with CIPN.
化疗引起的周围神经病变（CIPN）会对癌症患者的活动能力和生活质量产生有害影响。振动疗法作为一种CIPN干预措施显示出前景，但研究较少。我们调查了低强度振动（LIV）对患有CIPN的癌症幸存者的可行性和初步疗效。
我们对患有持续性CIPN症状的成年癌症幸存者进行了一项试点随机对照试验。参与者被随机分配到每天两次的LIV疗程（每次10分钟；30赫兹，0.4克），持续12周，或接受常规护理（UC）。我们通过入组、留存、依从性和不良事件（AE）报告来评估可行性。我们通过患者报告的CIPN症状（癌症治疗功能评估/妇科肿瘤学组神经毒性）、疼痛（简明疼痛量表）、疲劳（患者报告结局测量信息系统疲劳）和身体功能（晚年功能与残疾量表）的变化以及客观测量的身体功能（从椅子上站起时间、步速）、稳定性（姿势摆动）和活动能力（定时起立行走测试）来评估初步疗效。使用线性回归模型生成效应大小估计值（科恩d值）。
我们招募了目标样本的95%（n = 38，平均年龄：62.6±9.9岁，89%为女性，化疗结束后的中位时间：18[6 - 39]个月），20名参与者被随机分配到LIV组，18名被分配到UC组。试验留存率为97%，LIV的平均依从率为77%±18%。没有严重不良事件。与UC组相比，LIV组参与者报告感觉神经病变症状有更大改善（LIV组，+1.4±3.3分；UC组，+0.2±2.8分；科恩d值 = 0.45）和基本下肢功能有更大改善（LIV组，+5.3±8.5分；UC组，-0.7±9.2分；科恩d值 = 0.80），稳定性、活动能力和步态变化的效应大小为中等至较大（科恩d值 = 0.60 - 0.66）。
LIV是安全、可行的，并且在缓解患有CIPN的癌症幸存者的CIPN症状和改善身体功能方面显示出初步疗效。
